Salute e Benessere
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
– Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the first half of 2025, including its cash, cash equivalents, and revenues.
As of June 30, 2025, the Company’s amounted to €122.1 million and €24.6 million of short-term deposits , compared to cash and cash equivalents at €96.6 million as of December 31, 2024.
amounted to (€53.9) million in the first half of 2025, compared to (€48.3) million for the same period in 2024, while the R&D expenses for the first half of 2025 were stable at (€45.2) million, compared to the first half of 2024. The increase in net cash used in operating activities is mainly due to working capital evolution and the net cash impact of the Company’s pipeline prioritization plan in the first half of 2025.
for the first half of 2025 amounted to (€24.8) million, compared to €8.9 million generated in the first half of 2024. The change is mostly due to the new subscription of deposits during the period.
for the first half of 2025 amounted to €104.9 million, compared to €22.6 million in the first half of 2024. The net cash generated from financing activities primarily comes from the receipt of the gross proceeds of €115.6 million (net proceeds of €108.5 million) from the second tranche of the previously announced structured financing of up to €348 million (the “Structured Financing”) in May 2025.
The $10 million (gross proceeds) milestone payment from Chia Tai Tianqing Pharmaceutical Group, Co., LTD (“CTTQ”) that was due within 30 days of the closing of the second tranche of the Structured Financing, was received on July 7, 2025, and will impact the second half 2025 cash flow.
Considering its current cost structure and forecasted expenditures, the Company estimates that its cash and cash equivalents and short-term deposits , combined with the receipt of the $10 million (gross proceeds) milestone payment from CTTQ in July 2025, and the effective implementation of the Company’s pipeline prioritization plan, should allow it to fund its operations as currently planned until the end of the third quarter of 2026 .
The Company will need to raise additional funds to achieve its long-term objectives for the development and potential commercialization of lanifibranor through other potential public offerings or private placements and potential strategic options such as business development partnerships, merger and acquisition transactions and/or licensing agreements.
Over the first half of 2025, the Company recorded a on cash and cash equivalents of (€1.0) million, compared to a positive effect of €0.1 million for the first half of 2024, due to the evolution of EUR/USD exchange rate.
The revenues for the first half of 2025 amounted to €4.5 million, compared to none generated for the same period in 2024.
The revenues recorded by the Company in the first half of 2025 consist mainly of the $10 million (net proceeds of €8.6 million) milestone payment invoiced to CTTQ and the $5 million (€4.3 million) credit notes recognized under the license agreement with CTTQ following the closing of the second tranche of the Structured Financing in May 2025.As mentioned above, the receipt of the $10 million (gross proceeds) milestone payment from CTTQ in July 2025 will impact the cash flow of the second semester of 2025.
Wednesday September 29, 2025 (after U.S. market close)
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com
Preliminary, non-audited financial information
Short-term deposits were included in the category “other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available.
Cf. press release date May 5, 2025
Cf. press release date October 14, 2024
This estimate is based on the Company’s current business plan, taking into account the anticipated completion of the Company's pipeline prioritization plan and excludes any potential milestones payable to or by the Company, any potential further proceeds from the Structured Financing, and any additional expenditures related to other product candidates or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated.
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti